Beckman Coulter, Inc.
 

Products

   
   
 
 

  Osteoporosis

Printer Friendly


Related Product Information

 

Hybritech Ostase


Ostase® is a premier indicator of bone turnover. It is the only blood test available in the USA to aid in the management of postmenopausal osteoporosis.


 
Products Offerings for the Management of Osteoporosis
 
Test Name Description or Indication Instrument(s) Type of Lab/Discipline

Access® Ostase®

Hybritech Ostase is a premier indicator of bone turnover. It is the only blood test available in the USA to aid in the management of postmenopausal osteoporosis. Immunoassay
 

More Info

What is Osteoporosis?

Osteoporosis is a disease, often with no detectable symptoms, that affects between 15 to 25 million people in the United States. Often the first sign of Osteoporosis is a bone fracture in the hip or wrist. Bone is always breaking down and rebuilding as part of the natural cycle, but when Osteoporosis strikes, this process is thrown out of balance. Bones can become brittle, many times resulting in debilitating fractures. This condition is especially common in postmenopausal women, and the lack of estrogen is believed to be the cause. Treatment often includes Hormone Replacement Therapy (HRT), bisphosphonate or calcitonin. Fortunately, postmenopausal osteoporosis in preventable.
 

What do I need to know?

There is new hope for managing Osteoporosis. A laboratory blood test, Ostase, can accurately measure how well bone is responding to hormone replacement therapy. The test measures the amount of a specific bone alkaline phosphotase (BAP) in the blood. This gives doctors a clear indication of whether the therapy is successful in reducing bone loss.
 

Why Use Ostase?

Ostase, a biochemical marker of bone turnover, has been demonstrated effective in managing postmenopausal women on osteoporotic therapy. Ostase provides physicians and patients with a timely means of assessing therapy compliance and efficacy, whereas the traditional bone mineral density measurements require a minimum of one to two years to detect changes in bone. In addition, the blood-based Ostase test provides convenience and reliability, with a simple blood sample collection rather than a more variable urine test.

Currently, a bone mineral density test is required to diagnose Osteoporosis. If a diagnosis is confirmed, therapy begins. At this point, the physician and patient can choose how progress will be monitored. With Ostase as the follow-up test, the success of therapy can be documented after only six months. Bone mineral density tests, on the other hand, require a minimum of twelve to twenty-four months on therapy to detect changes in bone. With Ostase, you can see accurate, measurable results in less than half the time required of bone mineral density testing. Wouldn't you rather have the assurance of knowing, early on, that your therapy is working?
 

Ask for it by name. Ostase, from Beckman Coulter

 

Note: Not all products are available in all countries.
 

 
 
Home | Products | Customer Support | Resource Center
Employment | Our Company | Contact Us | Site Map
 Privacy©1998 - 2008 Beckman Coulter, Inc.